KIM-1 was identified as a possible biomarker of kidney damage in patients treated with cisplatin when comparing its expression between participants who did not have any degree of nephrotoxicity and those who had, according to the CTCAE or AKIN, but not when RIFLE was adopted. This evidence concerns the gene HAVCR1 and Nephropathy.